Effect of psoriasis therapy on VEGF and its soluble receptors serum concentrations

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue 3, 2012, Pages 302-307

  Flisiak, I ^a   Zaniewski, P ^a   Rogalska Taranta, M ^a   Chodynicka, B ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

DITHRANOL; SALICYLIC ACID; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME IMMUNOASSAY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PSORIASIS;

ADULT; AGED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SEVERITY OF ILLNESS INDEX; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84857359458     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04053.x     Document Type: Article

References (29)

1. Simonetti O, Lucarini G, Goteri G, et al. VEGF is likely a key factor in the link between inflammation and angiogenesis in psoriasis: results of an immunohistochemical study. Int J Immunopathol Pharmacol 2006; 19: 751-760. (Pubitemid 46145039)
2. Henno A, Blacher S, Lambert CA, et al. Histological and transcriptional study of angiogenesis and lymphangiogenesis in uninvolved skin, acute pinpoint lesions and established psoriasis plaques: an approach of vascular development chronology in psoriasis. J Dermatol Sci 2010; 57: 162-169.
3. Chua RA, Arbiser JL. The role of angiogenesis in the pathogenesis of psoriasis. Autoimmunity 2009; 42: 574-579.
4. Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res 2000; 55: 15-35.
5. Bhushan M, McLaughlin B, Weiss JB, Griffiths CE. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol 1999; 141: 1054-1060. (Pubitemid 30046195)
6. Ren X, Li J, Zhou X, et al. Recombinant murine interleukin 4 protein therapy for psoriasis in a transgenic VEGF mouse model. Dermatology 2009; 219: 232-238.
7. Teige I, Hvid H, Svensson L, Kvist PH, Kemp K. Regulatory T cells control VEGF-dependent skin inflammation. J Invest Dermatol 2009; 129: 1437-1445.
8. Man XY, Yang XH, Cai SQ, Bu ZY, Zheng M. Overexpression of vascular endothelial growth factor (VEGF) receptors on keratinocytes in psoriasis: regulated by calcium independent of VEGF. J Cell Mol Med 2008; 12: 649-660. (Pubitemid 351555142)
9. Kiselyov A, Balakin KV, Tkachenko SE. VEGF/VEGFR signalling as a target for inhibiting angiogenesis. Expert Opin Investig Drugs 2007; 16: 83-107. (Pubitemid 44964169)
10. Deeva I, Mariani S, De Luca C, et al. Wide-spectrum profile of inflammatory mediators in the plasma and scales of patients with psoriatic disease. Cytokine 2010; 49: 163-170.
11. Flisiak I, Chodynicka B, Porȩbski P, Flisiak R. Association between psoriasis severity and transforming growth factor beta 1 and beta 2 in plasma and scales from psoriatic lesions. Cytokine 2002; 19: 121-125. (Pubitemid 35216192)
12. Flisiak I, Zaniewski P, Chodynicka B. Plasma TGF-β1, TIMP-1, MMP-1 and IL-18 as combined biomarker of psoriasis activity. Biomarkers 2008; 13: 549-556. (Pubitemid 352044263)
13. Zhou CL, Yu XJ, Chen LM, Jiang H, Li CY. Corticotropin-releasing hormone attenuates vascular endothelial growth factor release from human HaCaT keratinocytes. Regul Pept 2010; 160: 115-120.
14. Kakurai M, Demitsu T, Umemoto N, et al. Vasoactive intestinal peptide and inflammatory cytokines enhance vascular endothelial growth factor production from epidermal keratinocytes. Br J Dermatol 2009; 161: 1232-1238.
15. Zeichner JA, Lebwohl MG, Menter A, et al. Psoriasis process of care consensus panel. Optimizing topical therapies for treating psoriasis: a consensus conference. Cutis 2010; 86 (Suppl 3): 5-31.
16. Kamili QU, Menter A. Topical treatment of psoriasis. Curr Probl Dermatol 2009; 38: 37-58.
17. 1 as a biomarker of psoriasis activity and treatment efficiency. Biomarkers 2003; 8: 437-443. (Pubitemid 37509176)
18. Flisiak I, Myśliwiec H, Chodynicka B. Effect of psoriasis treatment on plasma concentrations of metalloproteinase-1 and tissue inhibitor of metalloproteinases-1. J Europ Acad Dermatol Venereol 2005; 19: 418-421. (Pubitemid 40946092)
19. Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244. (Pubitemid 8387357)
20. Creamer D, Allen M, Jaggar R, Stevens R, Bicknell R, Barker J. Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor. Arch Dermatol 2002; 138: 791-796. (Pubitemid 34625524)
21. Kendall RL, Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1 and its heterodimerization with KDR. Biochem Biophys Res Commun 1996; 226: 324-328. (Pubitemid 26331903)
22. Roya H, Bhardwaja S, Ylä-Herttualaa S. Biology of vascular endothelial growth factors. FEBS Lett 2006; 580: 2879-2887.
23. Cébe-Suarez S, Zehnder-Fjällman A, Ballmer-Hofer K. The role VEGF receptors in angiogenesis; complex partnerships. Cell Mol Life Sci 2006; 63: 601-615.
24. Fink AM, Cauza E, Hassfeld W, et al. Vascular endothelial growth factor in patients with psoriatic arthritis. Clin Exp Rheumatol 2007; 25: 305-308. (Pubitemid 46851437)
25. Nofal A, Al-Makhzangy I, Attwa E, Nassar A, Abdalmoati A. Vascular endothelial growth factor in psoriasis: an indicator of disease severity and control. J Eur Acad Dermatol Venereol 2009; 23: 803-806.
26. Barile S, Medda E, Nisticò L, et al. Vascular endothelial growth factor gene polymorphisms increase the risk to develop psoriasis. Exp Dermatol 2006; 15: 368-376. (Pubitemid 44056484)
27. Schonthaler HB, Huggenberger R, Wculek SK, Detmar M, Wagner EF. Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis. Proc Natl Acad Sci USA 2009; 106: 21264-21269.
28. Bussolati B, Dunk C, Grohman M, Kontos CD, Mason J, Ahmed A. Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide. Am J Pathol 2001; 159: 993-1008. (Pubitemid 32847190)
29. Canavese M, Altruda F, Ruzicka T, Schauber J. Vascular endothelial growth factor (VEGF) in the pathogenesis of psoriasis-a possible target for novel therapies? J Dermatol Sci 2010; 58: 171-176.